中印廉价药抢占全球市场 发达国家或“反击”
2011年09月21日 06:37来源：中广网
据美国《纽约时报》9月19日报道，中国和印度制药商占据全球廉价医药市场很大份额，现在更是生产全球零售药品中80%的活性成分。现在，中印制药公司已经开始进军高端生物药品市场，这可能缓解全球病人面临的窘况，但同时也将引来发达国家大制药公司的反击。
发达国家和制药行业10年前曾承诺，放弃艾滋病药物的专利权和收益，以应对艾滋病对全世界的威胁。当时，癌症、糖尿病以及其他非传染性疾病对人类的威胁还不算严重。可是现在，死于这些非传染性疾病的人已经占全球死亡人数的三分之二。美国政府不支持穷国获得治疗癌症和其他非传染性疾病药物的专利权，以此鼓励进一步发明创新。
为了改变这种情况，中印两国向高端生物制药行业投入巨资。印度医药公司Cipla主席尤素夫·哈米德（Yusuf K. Hamied）说，他正与中国伙伴一起投资1.65亿美元（约合10.5亿元人民币），在中国和印度建造能生产至少12种生物药物的工厂。其他印度公司也在建造类似工厂。
哈米德还说，由于这些药物多数是由遗传工程细菌制成，它们在出售前必须经过广泛测试。一旦测试完成，哈米德承诺将以通常价格的三分之一出售它们。一旦收回成本，价格还将继续降低。（杨柳）
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2011年5月正式出版的《中国特色医疗金鉴》登载的刘君主任及其机构事迹 |
| |
|
|
Indian low-cost drugs to seize global markets in developed countries or "fight back"
At 06:37 on September 21, 2011 Source: Zhongguang Wang
According to the U.S. "New York Times" reported on September 19, pharmaceutical manufacturers in China and India account for a large share of the global pharmaceutical market of cheap, now it is producing 80% of global retail pharmaceutical active ingredients. Now, the Indian pharmaceutical companies have begun to enter the high-end bio-pharmaceutical market, which could ease the predicament faced by patients around the world, but will also lead to large pharmaceutical companies in developed countries back.
Developed countries and the pharmaceutical industry 10 years ago promised to give AIDS drugs, patents and benefits to address the threat of AIDS on the world. At that time, cancer, diabetes and other non-communicable diseases, the threat to humans is not too serious. But now, died of these non-communicable diseases have accounted for two thirds of global deaths. The U.S. government does not support the poor access to treatment of cancer and other non-communicable diseases, drug patents, in order to encourage further invention and innovation.
To remedy this situation, China and India to invest heavily in high-end bio-pharmaceutical industry. Indian pharmaceutical company Cipla chairman Yusuf Hamid (Yusuf K. Hamied) said he is working with Chinese partners to invest $ 165 million (about 1.05 billion yuan), built in China and India can produce drugs at least 12 kinds of biological factory. Other Indian companies are also building a similar plant.
Hamid also said that because most of these drugs are made by genetic engineering of bacteria, they must be extensively tested before sale. Once testing is completed, Hamid commitment to one-third of the price will usually sell them. Once the recovery of costs, prices will continue to decrease. (Willow)
|
